Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Placer Biosciences General Information
Placer Biosciences is a preclinical-stage biotech company developing novel, non-psychoactive cannabinoid prodrugs and engineered enzymes as potential treatments for inflammatory bowel diseases. The company recently acquired the legacy cannabinoid drug development assets of Graphium Biosciences from Range Impact, including intellectual property and early-stage programs targeting gastrointestinal inflammation. No clinical results have been reported to date.[4][6][8]
Contact Information
Drug Pipeline
Pre-clinical
Key Partnerships
Range Impact retains a minority equity interest via warrants as part of the asset sale agreement; no major pharma partnerships disclosed yet.[6][7]
Placer Biosciences Funding
No funding data available
To view Placer Biosciences's complete valuation and funding history, request access »